Ardelyx (ARDX) Competitors $6.21 -0.21 (-3.27%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$6.21 0.00 (0.00%) As of 09/19/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARDX vs. AXSM, NUVL, TGTX, MRUS, CRSP, PTCT, KRYS, PCVX, ACAD, and ACLXShould you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Axsome Therapeutics (AXSM), Nuvalent (NUVL), TG Therapeutics (TGTX), Merus (MRUS), CRISPR Therapeutics (CRSP), PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry. Ardelyx vs. Its Competitors Axsome Therapeutics Nuvalent TG Therapeutics Merus CRISPR Therapeutics PTC Therapeutics Krystal Biotech Vaxcyte ACADIA Pharmaceuticals Arcellx Axsome Therapeutics (NASDAQ:AXSM) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends. Do insiders & institutionals hold more shares of AXSM or ARDX? 81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 22.3% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media prefer AXSM or ARDX? In the previous week, Axsome Therapeutics had 17 more articles in the media than Ardelyx. MarketBeat recorded 22 mentions for Axsome Therapeutics and 5 mentions for Ardelyx. Ardelyx's average media sentiment score of 0.75 beat Axsome Therapeutics' score of 0.70 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 13 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, AXSM or ARDX? Axsome Therapeutics has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Which has stronger valuation & earnings, AXSM or ARDX? Ardelyx has lower revenue, but higher earnings than Axsome Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAxsome Therapeutics$495.03M11.69-$287.22M-$5.07-22.87Ardelyx$333.61M4.49-$39.14M-$0.23-27.00 Do analysts rate AXSM or ARDX? Axsome Therapeutics presently has a consensus target price of $177.86, suggesting a potential upside of 53.39%. Ardelyx has a consensus target price of $11.70, suggesting a potential upside of 88.41%. Given Ardelyx's higher possible upside, analysts clearly believe Ardelyx is more favorable than Axsome Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 3.13Ardelyx 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.10 Is AXSM or ARDX more profitable? Ardelyx has a net margin of -14.60% compared to Axsome Therapeutics' net margin of -49.88%. Ardelyx's return on equity of -36.57% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Axsome Therapeutics-49.88% -283.22% -33.06% Ardelyx -14.60%-36.57%-13.42% SummaryAxsome Therapeutics and Ardelyx tied by winning 8 of the 16 factors compared between the two stocks. Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDX vs. The Competition Export to ExcelMetricArdelyxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.50B$2.57B$5.80B$10.47BDividend YieldN/A55.04%5.61%4.57%P/E Ratio-27.0022.8180.4926.84Price / Sales4.49712.96535.85125.78Price / CashN/A27.8326.0131.15Price / Book8.515.2915.776.42Net Income-$39.14M$32.95M$3.30B$271.73M7 Day Performance-4.90%1.99%3.93%2.82%1 Month Performance1.64%2.97%5.32%6.60%1 Year Performance1.31%-2.98%80.88%28.60% Ardelyx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDXArdelyx4.2683 of 5 stars$6.21-3.3%$11.70+88.4%+1.3%$1.50B$333.61M-27.0090AXSMAxsome Therapeutics4.8557 of 5 stars$129.29+3.3%$177.86+37.6%+21.0%$6.25B$385.69M-25.50380Insider TradeAnalyst RevisionNUVLNuvalent3.1199 of 5 stars$79.83-1.3%$120.91+51.5%-29.0%$5.83BN/A-16.2940Insider TradeTGTXTG Therapeutics4.29 of 5 stars$32.38+0.5%$46.25+42.8%+31.3%$5.11B$329M87.51290Trending NewsAnalyst RevisionMRUSMerus2.8434 of 5 stars$67.19-0.4%$88.75+32.1%+37.3%$5.10B$36.13M-12.2237News CoveragePositive NewsAnalyst ForecastCRSPCRISPR Therapeutics2.9186 of 5 stars$54.10-1.4%$71.60+32.3%+29.3%$4.99B$37.31M-9.96460PTCTPTC Therapeutics3.7742 of 5 stars$56.95-0.5%$69.00+21.2%+65.1%$4.55B$806.78M8.171,410KRYSKrystal Biotech4.9541 of 5 stars$145.20-3.4%$210.38+44.9%-11.2%$4.35B$290.52M29.51210PCVXVaxcyte2.0065 of 5 stars$32.41-1.8%$130.00+301.1%-72.4%$4.29BN/A-7.89160Positive NewsACADACADIA Pharmaceuticals4.2508 of 5 stars$25.39+0.5%$28.88+13.7%+47.7%$4.26B$957.80M19.09510ACLXArcellx2.2835 of 5 stars$71.11-2.1%$114.31+60.7%-10.1%$4.03B$107.94M-20.7980Positive NewsInsider Trade Related Companies and Tools Related Companies AXSM Competitors NUVL Competitors TGTX Competitors MRUS Competitors CRSP Competitors PTCT Competitors KRYS Competitors PCVX Competitors ACAD Competitors ACLX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARDX) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | SponsoredThis soon could be the most precious company in AmericaAI is devouring power at an unprecedented rate. Google alone expects its annual electricity bill to jump by $2...True Market Insiders | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
